<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The treatment programme (regimen I) we designed in 1982 for advanced Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was modified in 1986 as regimen IIA and IIB for patients presenting without or with bone marrow (BM) and/or <z:mp ids='MP_0008912'>nervous</z:mp> system involvement, respectively </plain></SENT>
<SENT sid="1" pm="."><plain>Following a 5-week course of cytoreductive chemotherapy, including <z:chebi fb="0" ids="28445">vincristine</z:chebi> (VCR), <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CPM), <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> (DXR), high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (HDMTX) and intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (ARAC), high-dose ARAC and <z:chebi fb="2" ids="27899">cisplatin</z:chebi> were given as a 4-day continuous infusion </plain></SENT>
<SENT sid="2" pm="."><plain>Regimen I continued with an additional 3-week course including VCR, CPM, DXR and HDMTX, which was omitted in regimen IIA </plain></SENT>
<SENT sid="3" pm="."><plain>In regimen IIB the initial cytoreductive chemotherapy was complemented by adding <z:chebi fb="0" ids="4911">etoposide</z:chebi> and increasing HDMTX doses, and by modifying the high-dose ARAC administration modality and was followed, once the bone marrow had recovered, by ifosfamide that concluded the programme </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 44 children (22 in regimen I and 22 in regimens IIA and IIB) were treated, with an overall response rate of 98% </plain></SENT>
<SENT sid="5" pm="."><plain>4 patients died as a result of treatment related complications </plain></SENT>
<SENT sid="6" pm="."><plain>Survival, progression-free and event-free survival rates were 73, 70 and 63%, respectively, for regimen I, and 82, 90 and 82%, respectively, for regimen IIA and IIB </plain></SENT>
<SENT sid="7" pm="."><plain>A short chemotherapeutic regimen, using alternating phase-specific and non-specific agents, is able to cure the majority of patients with advanced Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>